Events

New Activities

Webinar - One Health special issue ...

To celebrate One Health Awareness Month, ISAC will host a 60-minute webinar showcasing cutting-edge research from the One Health Special ...

Register
Innovations and Challenges in HIV ...

The International Society of Antimicrobial Chemotherapy (ISAC) and the International Society for Infectious Diseases (ISID) hosted a special joint World ...

Watch
Session 2: MDR infections in the ICU: ...

Join us for the second of the three-part webinar series, Critical Care Infectious Diseases – Hot Topics and Upcoming ...

Watch
Session 1: Optimising antimicrobial ...

On demand coming soon Join us for the first in a three-part webinar series exploring cutting-edge developments in critical care ...

Watch
Challenges of Antimicrobial Resistances ...

ISAC / symposium at Asia Pacific Congress of Clinical Microbiology and Infections (APCCMI), Bangkok, November 2025 The symposium focused on the ...

Watch
Crazy Enough to Work: Wild Ideas to ...

The AMR Declaration Trust, in collaboration with the Alliance for the Prudent Use of Antibiotics (APUA), hosted an impactful session ...

Watch
Microscope

4th Polymyxin Conference

Presentations from the 4th International Conference on Polymyxins which ISAC was proud to have endorsed.

Polymyxins in the Era of CROs: Opportunities and Challenges
Co-Chairs: Profs Jian Li and Jing Zhang
8-10 October 2024, Suzhou, China

The conference explored the latest advancements across all major facets of the polymyxin class of antibiotics. Polymyxins are a last-line therapeutic option for treating life threatening infections caused by Gram-negative 'superbugs,' including the WHO priority pathogens Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Day 1 
Welcome address  Jian Li / J. Zhang
TREATMENT OF LIFE THREATENING INFECTIONS DUE TO MDR GRAM NEGATIVE BACILLI  David Paterson
Infections Caused by MDR Gram-negative Pathogens: Chinese Perspectives Minggui Wang
Three different polymyxin products in China: Polymyxin B, colistin and colistin methanesulphonate (CMS) Jian Li
Clinical Use of Colistin Methanesulfonate (CMS) and Polymyxin B in Critically-ill Patients Visanu Thamlikitkul
Clinical use of colistin methanesulfonate in patients. Spanish perspectives  Juan-Pablo Horcajada
Clinical Use of Colistin Sulfate in Critically Ill Patients  Baiyi Chen
Clinical use of Polymyxins in critically-ill pediatrics patients  Qing Cao
Nephrotoxicity of Polymyxins in critically-ill patients: risk factors & toxicodynamics  Andrea LH Kwa
Pharmacokinetics of Polymyxins in Different Types of Patients  Gauri Rao
Pharmacokinetics/pharmacodynamics of polymyxins  Cornelia B. Landersdorfer
Selecting the Right Dose of Colistin and Polymyxin B Visanu Thamlikitkul
The right dose of colistin sulfate: Are we there yet? Miao Yan
Therapeutic Drug Monitoring of Polymyxins in patients: Spanish perspectives Sònia Luque
Therapeutic drug monitoring of polymyxins in patients Chinese perspectives Yaxin Fan
The Most Pressing Needs To Be Studied By Innovative Clinical Trials Juan-Pablo Horcajada
Overview of Adaptive and Platform Trial Designs Xiaofang Wang
Innovative Endpoints in Infectious Diseases Clinical Trials Sean W. X. Ong
The PRACTical Trial Design David Paterson
Day 2
One Health of polymyxin resistance Yang Wang
WHAT CAN WE LEARN FROM INHALED COLISTINMETHATSODIUM IN CYSTIC
FIBROSIS PATIENTS?		 Niels Høiby
Inhaled polymyxins in critically-ill patients  Ilias Karaiskos
Pharmacokinetics/Pharmacodynamics of Inhaled Polymyxins Yu-Wei Lin
Inhaled Polymyxins: Importance of Formulation and Delivery Qi (Tony) Zhou
Nebulized polymyxins for VAP: Methodological considerations and lessons
from experimental studies		 Yinggang Zhu
China Antimicrobial Surveillance Network（CHINET）  Dandan Yin
Polymyxin antimicrobial susceptibility testing & ChiCAST breakpoint  Qiwen Yang
Determination of polymyxin breakpoints underpinned by PK/PD Xingchen Bian
Difficult-to-treat Gram-negative Infections: Getting the most out of available agents by
Diagnostic Combination Platform		 Andrea LH Kwa
Combination therapy of polymyxins: PK/PD is the key Wanzhen Li
Controlled Clinical Studies of Polymyxin Combination Visanu Thamlikitkul
Clinical evaluation of polymyxin combination therapy against CRO infections Xiaohua Qin
Antibacterial Drug Discovery and Development Programs and Preclinical and Clinical Services
at NIAID		 Zuoyu Xu
Development of BRII-693 -- a novel synthetic lipopeptide for top priority MDR pathogens Yao Zhang
EVER206: Next Generation Polymyxin for the Treatment of Highly Resistant Gram-Negative Bacterial Infections Sunny Zhu
POLYMYXIN ACTIVITY AGAINST BIOFILM Niels Høiby
The story of Mcr Jian-Hua Liu
Epidemiology and evolution of colistin-resistant Enterobacterales Hui Wang
Day 3
EFFECTS OF POLYMYXIN ON BACTERIAL BIOFILM INFECTIONS: FROM LABORATORY TO CLINIC Zhijun Song
Inhalation of polymyxins: Efficacy shown within two hours using sputum smears Xiaoping Huang
EDGE OF ETERNITY Dongdong Zhao/ Chris Zhao
Present and future of intravenous colistin methanesulfonate in treating pneumonia: The shift towards nebulized colistin methanesulfonate   Luisa Sorlí
Population Pharmacokinetics and Dose Optimization of Polymyxin B in Critically Ill Burn Patients  Jun Yang
Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study  Yueliang Xie